Insulet Corporation: A Long-Term Owner's Perspective

On the demand side, this business has stable, growth-leaning long-term demand. In its 2025 Standards of Care in diabetes technology, the ADA explicitly states that automated insulin delivery (AID) systems are the preferred delivery method for improving glycemic control and reducing hypoglycemia risk in type 1 diabetes, and that insulin pumps may also be considered for type 2 diabetes patients who require multiple daily insulin injections. The company goes further, disclosing that Omnipod 5 is already the only AID system in the U.S. cleared for both type 1 and type 2 diabetes. That means it faces not a mature, saturated market but a penetration curve that is still expanding.

Business understandability score: 4/5

The point I deduct is not because the business is complex, but because, although the product is intuitive and the demand is clear, its profit outcomes are affected by reimbursement, distribution, quality control, FDA compliance, and CGM ecosystem partnerships. These factors make the "stability on the books" somewhat lower than a consumer-goods-style pattern of simple repeat purchases.

Industry and Competitive Landscape

I define this industry as a growth-stage subsegment within diabetes technology, not a mature-stage one. There are three reasons. First, AID has gradually been pushed toward a more central position in clinical guidelines. Second, as far back as 2021 the company estimated that only about one-third of U.S. type 1 diabetes patients use insulin pumps, with even lower penetration internationally and far lower usage among insulin-treated type 2 diabetes patients. Third, the company's 2026 investor materials still define the current market as a TAM of roughly $30 billion or more, and continue to revise the long-term TAM upward. These TAM figures carry an obvious management-perspective element and should be treated as company estimates rather than audited facts.

On the competitive landscape, the main pump competitors Insulet names directly in its 2025 10-K include Medtronic Diabetes and Tandem Diabetes Care, as well as the new entrant Beta Bionics. At the same time, Insulet is not an isolated system; its interoperability with Dexcom's and Abbott's CGMs is an important part of its product competitiveness. In other words, PODD competes both with pump makers and within the larger "diabetes closed-loop ecosystem." Whoever can secure more physician prescriptions, run more smoothly through pharmacy channels, and most reliably deliver the pump, algorithm, and sensor experience is more likely to capture the industry's profit pool.

In its investor materials, the company calls itself the "most requested and most prescribed" AID system in the U.S., with about a 66% share of new AID customer starts in 2025, and states that it has ranked first in new-customer starts in both the U.S. and Europe since 2023. These are all company-disclosed figures, not third-party market-share conclusions I have independently verified, but they at least indicate that the company is currently not a marginal participant and has a real chance of becoming one of the strongest players in the category.

On pricing power, my judgment is "yes, but not unlimited." On the positive side, the company's 2024 gross-margin improvement was explicitly attributed to price gains in the U.S. pharmacy channel and international markets, manufacturing efficiency improvements, and procurement savings; in 2025, gross margin rose further from 69.8% to about 71.6%. On the negative side, medical devices are ultimately constrained by reimbursement policy, healthcare-cost negotiations, and international government pricing mechanisms, and overseas markets in particular are more prone to price pressure. So it is not luxury-goods-style free pricing power, but neither is it entirely without bargaining strength.

Industry attractiveness score: 4/5

This is a "good company in a good industry," not "a standout in a bad industry." But it is not a risk-free golden category either: technology iteration, sensor compatibility, FDA oversight, and competitors' product cadence will all keep shaping the landscape.

Moat and Management

Moat Assessment

Insulet's moat is not a single-point breakthrough but a stacking of multiple factors.

Start with brand and customer mindshare. Omnipod's tubeless design is highly differentiated in the diabetes pump market; the company's investor materials say it had more than 600,000 active customers in 2025, supported in the U.S. by 50,000 pharmacies and more than 30,000 active prescribing physicians. If these figures are broadly reliable, they show that Omnipod is no longer merely "a device" but a brand gateway with a patient community, physician habits, and payer coverage.

Next, switching costs. In diabetes management, switching is not as simple as swapping a piece of hardware. Patient habits, physician education, insurance coverage, sensor compatibility, algorithm experience, customer support, and refill processes all create friction. The company itself treats customer retention as the key to revenue growth, which by itself shows that retention is an important part of the business flywheel. I view this type of switching cost as a "clinical and behavioral habit" lock-in rather than a legal one; the stickiness is real.

Distribution advantage is the part of Insulet that is most easily underestimated. U.S. pharmacy accessibility, the wholesale/distribution system, payer-coverage negotiations, and parallel international direct sales and distribution make its product more like "a medical solution you can actually get" than one that is "technically the best but unobtainable." The company discloses that in 2025 Omnipod 5 covered 19 of the 25 global markets it serves, and that 86% of Omnipod sales went through intermediaries. This does bring concentration risk, but it also shows how deep the distribution network already is.

Regulatory and intellectual-property barriers are also real. Insulin pumps and closed-loop algorithms are not asset-light software startups; competitors must clear FDA/CE approval, manufacturing validation, clinical data, software safety, and quality systems. PODD also disclosed in its 2025 annual report that its litigation against EOFlow secured a permanent injunction and a $59.4 million award, which to some degree shows that its IP barrier is not merely on paper.

On scale and operating capability, I believe the company has entered a "bigger is stronger" regime. Its investor materials say it has invested more than $1 billion in manufacturing and supply chain, describing these investments as a deep, wide moat that "capital alone cannot easily replicate." That is a company claim, but the financials at least support one thing: as revenue grew from $1,099 million in 2021 to $2,708 million in 2025, gross margin rose from 68.4% to about 71.6% and operating margin rose from 11.5% to 17.5%, showing that the expansion of scale did not dilute profitability but rather strengthened the cost structure.

But I will not call this a perfect moat. It has no true network effects and is not a lowest-cost-supplier monopoly; and its dependence on Dexcom and Abbott sensor interoperability means ecosystem partnerships matter. To replicate it, competitors would need years of product iteration, heavy compliance investment, distribution build-out, and a sustained after-sales system. I lean toward seeing this moat as slowly widening, but the two device corrections in 2026 remind us that the weakest link in the moat is not the market but manufacturing and quality discipline.

Moat strength score: 4/5

Management and Capital Allocation

On management, both the strengths and the reservations are clear.

On the positive side, Insulet's governance framework is not bad. The company has a clawback provision, clear stock-ownership guidelines, and anti-hedging/anti-pledging policies; in 2025, most of the compensation for the CEO and other executives was variable, with long-term incentives primarily in PSUs, RSUs, and options, and about 92% of the CEO's target total compensation variable and about 81% long-term. By design, this is not a team that "takes only cash salary and sidelines shareholders."

But from a "Buffett-style owner" angle, ownership alignment is not strong. As of March 23, 2026, all directors and executives together held 250,199 shares, less than 1% of total shares outstanding; current CEO Ashley McEvoy herself discloses ownership of 13,597 shares, also under 1%. Compared with a true founder-type or high-ownership operator, the shareholder-management bond is on the weaker side.

Another reservation I should state honestly is that the top of management is still fairly new. The proxy shows that Ashley McEvoy has served as PEO/CEO since April 28, 2025, while predecessor Hollingshead remained PEO for the first four months of 2025. In other words, what you are evaluating today is a company whose business is mature but whose top organization is still re-gelling. For a long-term investor, this is not a fatal problem, but it means "management credibility" needs more time to be proven.

On capital allocation, Insulet has broadly prioritized cash toward reinvestment and has indeed turned that reinvestment into higher revenue and margins in recent years, which is a plus. The company pays no dividend; in 2025 it repurchased $59.6 million mainly to offset equity-incentive dilution; and by Q1 2026 it spent another $300 million on an ASR repurchase. The problem is that this large repurchase was not necessarily made cheaply: based on the Q1 shareholders'-equity statement showing about 1.251 million shares repurchased at a cost of about $302.7 million, the average repurchase price works out to roughly $240 per share, while the current price is only $144.94. This is an inference based on disclosed share count and total cost; it cannot be guaranteed to exactly equal the ASR's final settlement average price, but it does at least show that this repurchase can hardly be described as "buying back aggressively when clearly undervalued."

In addition, the proxy discloses a governance detail worth putting on the record: in the first three quarters of 2025, the spouse of director Jessica Hopfield had worked at one of the company's distributors, to which the company recognized $511.6 million of revenue in the period; the company states the terms were consistent with arm's-length dealing and that, as of October 1, 2025, this no longer constitutes a related-party transaction. From a disclosure-transparency standpoint, this is not a hidden matter; but from an owner's standpoint, I would list it as "a governance item to keep watching" rather than ignore it outright.

Management and capital-allocation score: 3/5

My summary is this: management is not untrustworthy, but it has not yet reached the level where "I barely need to worry about capital allocation." The institutional framework is adequate and the reinvestment record is good; however, low insider ownership, the CEO's short tenure, the unattractive repurchase timing, and the back-to-back 2026 quality events all make me more willing to extend "cautious trust" rather than "high trust."

Financial Quality and Owner Earnings

Key Financial Quality

The table below is compiled from the company's 2021-2025 10-Ks and Q1 2026 10-Q; gross margin, operating margin, free-cash-flow conversion, ROIC, net debt, and similar items are partly calculations based on the original financial data. The free-cash-flow definition follows the company's common usage, i.e., operating cash flow less capital expenditures; ROIC uses after-tax operating profit / (interest-bearing debt + shareholders' equity - cash) and is estimated at a 22% normalized tax rate, so it is an analytical estimate rather than a direct company disclosure.

The core conclusion on financial quality is vivid: high revenue growth, steadily improving gross margin, operating leverage beginning to be released, and a balance sheet far healthier than three years ago. Revenue grew at a CAGR of about 25.3% from 2021 to 2025; operating margin recovered from 2.9% in 2022 to 17.5% in 2025; the company generated $377.7 million of free cash flow in 2025 and $89.5 million in Q1 2026, both clearly above the past capacity-building phase.

But there are two significant items of noise in the financials that must be unpacked. First, 2024 net income was affected by the reversal of a deferred-tax valuation allowance; the company disclosed a $182.5 million tax benefit recognized that year, so the $418.3 million of 2024 net income does not fully represent operating cash profit. Second, 2025 net income was depressed by a $123.9 million loss on debt extinguishment, so the $247.1 million of 2025 net income also understates operating performance. With this company, you cannot fixate on the net-income line alone; operating profit, operating cash flow, and owner earnings matter more than net income.

On cash quality, the company's profits are broadly real, but more volatile than they appear on the surface. In 2025, operating cash flow reached $569.3 million, well above net income; part of this is because non-cash items such as the debt-extinguishment loss were added back. Cumulative free cash flow over the three years 2023-2025 was about $753 million, showing that the company has passed the "growth must keep burning cash" phase and entered the "growing while generating cash" phase. Free cash flow in 2021-2022 was weak or even negative, mainly tied to manufacturing capacity expansion and working-capital absorption; this looks more like stage-specific investment than a business model that cannot generate cash on its own.

On the balance sheet, as of Q1 2026, cash was $480.4 million, total debt net was $948.1 million, and net debt was about $467.7 million; on a rough LTM EBITDA basis, net debt/EBITDA is about 0.8x and interest coverage is about 12.5x, so near-term debt-servicing pressure is not heavy. At the end of 2025, net debt was only about $233 million and leverage was even lighter for a time; the Q1 increase was driven mainly by the ASR repurchase and higher capital expenditures. For a high-margin, high-growth medical-device company, this balance sheet is sound rather than aggressive.

Working capital carries two alarms worth remembering. First, both receivables and inventory are rising fast: net receivables at period end jumped from $240.2 million in 2023 and $252.5 million in 2024 to $516.9 million in 2025, and further to $544.7 million in Q1 2026; inventory rose from $303.2 million in 2021 to $462.5 million in Q1 2026. Second, the company discloses that most of its U.S. inventory is concentrated in a single location in Massachusetts and that some raw materials come from a single supplier, which amplifies both working-capital pressure and supply-chain disruption risk. There is no obvious sign of misstatement here, but it shows that PODD is not a "zero-inventory, zero-receivable" light-model company.

The change in share count is broadly acceptable. Shares outstanding at period end rose from about 69.18 million at the end of 2021 to about 70.39 million at the end of 2025, an increase of less than 2% over four years; in Q1 2026 it fell to about 69.26 million after repurchases. In other words, the company does have equity incentives, but by the results, historical dilution has not been severe. What truly deserves scrutiny is not "runaway dilution" but "whether the repurchase price is rational."

A Conservative Owner-Earnings Estimate

I look at owner earnings two ways.

Conservative basis: take trailing-twelve-month operating cash flow of $619.3 million directly, subtract capital expenditures of $203.6 million, then subtract capitalized software of $19.3 million, to arrive at about $396.4 million. The advantage of this basis is that it is simple and rigorous and counts all the real cash outflows; its drawback is that it treats a portion of clearly growth-oriented expansion spending as "maintenance spending," and therefore understates the company's true long-term distributable cash flow.

A basis closer to operating substance: take 2025 net income of $247.1 million, add back depreciation and amortization of $90.4 million, do not add back SBC in full because I treat it as a real shareholder cost, then account for the $123.9 million debt-extinguishment loss in 2025 as a non-recurring, non-operating item, and assume maintenance capital expenditures are roughly close to depreciation and amortization. On that basis, owner earnings in a neutral year are quite likely to exceed GAAP net income and land near $380-430 million. The word "near" here is an inference, not a direct company disclosure.

So, in valuation I choose $370 million as a conservative starting point, $385 million as a neutral starting point, and $410 million as an optimistic starting point. Against the current market cap of $10.18 billion, PODD trades at about 25.7x conservative LTM owner earnings; looking only at the company's free-cash-flow definition, it is about 24.5x. This is not a cheap valuation; it can only be called the "normal, somewhat expensive range for a quality growth stock."

Valuation, Margin of Safety, and Opportunity Cost

Current Valuation and Multiples

As of around May 29, 2026 (U.S. Eastern Time), PODD's share price is about $144.94, total market cap is about $10.18 billion, and the trailing P/E is about 33.9x.

On a rough LTM basis, PODD currently corresponds to about P/S 3.5x, EV/Sales 3.7x, EV/EBIT 21x, EV/EBITDA 17.7x, P/FCF 24.5x, P/B 7.8x. These multiples are not absurd, but they are clearly not the kind of deep undervaluation that "leaves room to be wrong."

A useful comparison: the LTM owner's yield on the conservative basis is about 3.9%, while the 10-year Treasury yields about 4.45%. This means that if you buy PODD today, you are accepting a trade structure where "the current cash return is below the risk-free rate, but you are compensated by future growth." Only when you have fairly high conviction in its growth and moat over the next 10 years does such pricing make sense. For more conservative investors, that usually implies needing a lower entry point.

Intrinsic-Value Estimate

Owner-Earnings Discount Method

The table below is my three-scenario DCF. Let me make a clear distinction: the starting owner earnings is an analytical assumption built on top of the conservative basis above; the growth rates, discount rates, and terminal growth rates are all assumptions; and the calculated results are inferences, not facts.

Within this framework, I give three price ranges:

By this measure, the current $144.94 sits roughly near the upper edge of the fair range: a clear premium to conservative intrinsic value, roughly flat to slightly above neutral value, and still a discount to optimistic value. It is not "clearly overvalued enough to require avoidance," but neither is it "clearly undervalued enough to warrant an immediate large position."

Relative Valuation

On relative valuation, putting PODD alongside its direct peers and adjacent high-quality diabetes-technology companies tells the story more clearly.

PODD's trailing P/E is even slightly above DXCM's, while DXCM held about $2.42 billion of cash and short-term securities as of Q1 2026 with a more comfortable debt structure; this shows the market is willing to grant PODD a fairly high growth expectation. On the other hand, using the latest quarter annualized for a rough comparison, PODD's EV/Sales is about 3.5x, below DXCM's roughly 5.9x but well above the roughly 1.2x of the still-recovering TNDM. This is a reasonable position: the market treats PODD as a quality growth stock but has not yet priced it like a top-tier asset such as DXCM.

Asset or Liquidation-Value Method

On an asset/liquidation basis, PODD is not cheap. Book shareholders' equity in Q1 2026 was about $1,303 million, corresponding to about 7.8x P/B on the current market cap; if you apply conservative haircuts to receivables, inventory, and fixed assets, the liquidation residual to shareholders is quite likely low, and could even be near zero. In other words, this is not a net-cash asset stock, nor an asset-protected investment; almost all of its value comes from future going-concern cash flow. That naturally raises my requirement for a margin of safety.

Margin of Safety and Opportunity Cost

My conclusion is clear: the margin of safety at the current price is insufficient.

The most fragile valuation assumption is not "whether growth slows a bit," but "whether the market keeps being willing to grant it the high multiple of a quality growth stock." If revenue still grows over the next 3-5 years but manufacturing/quality problems persist, T2D penetration falls short of expectations, or competitors win back share at the physician level, then EV/Sales and EV/EBIT are quite likely to contract together. For a company whose owner's yield is still below the 10-year Treasury, multiple compression could entirely swallow most of the shareholder return.

So, from the classic "good company or good price" framing, PODD is closer to "a good company, but a price not yet cheap enough for me to feel comfortable." For the ideal buy zone, I lean toward placing it at $110-120; an acceptable holding-price range is roughly $120-160; and if the price climbs back above $180 without a matching upside surprise in fundamentals, I would consider it clearly heading toward expensive. This is my opinion, not market consensus.

Compared with other opportunities, buying PODD at the current price is not necessarily clearly better than buying an index or locking in higher-grade bond yields. Its advantage is growth and potential long-term compounding; its disadvantages are single-stock concentration risk, quality-execution risk, and a valuation that is not cheap enough. If you could only hold 5 assets, I do not think PODD is strong enough near the current price to be a "must-include"; only when it returns to a more discounted range does it more deserve to occupy scarce capital.

Risks, Checklist, and Final Conclusion

Main Risks and the Bear Case

The most important risk is not short-term volatility but where permanent capital loss could come from.

First is competition and technology-substitution risk. Medtronic, Tandem, and Beta Bionics keep attacking on the pump side, while Dexcom and Abbott control the sensor-ecosystem gateway; if the closed-loop experience, physician preference, or payer coverage reverses in the future, Insulet's new-customer share and pricing power could both be eroded.

Second is quality and regulatory risk. The company already had one voluntary device correction in March 2026; on May 26 it issued a second voluntary correction over a manufacturing issue involving about 7 million Pods, and the company expects this could generate up to $50 million in costs in 2026. Management says it does not change long-term growth or 2026 guidance, but once such events persist, the impact is not only on cost but on brand, physician trust, and regulatory relationships.

Third is channel and customer-concentration risk. In 2025, the three largest distribution customers together contributed about 78% of total revenue, and 86% of Omnipod sales went through intermediaries; Drug Delivery depends almost entirely on Amgen, with the agreement running to the end of 2028. If any one of these relationships changes unfavorably, the swings in the financials will be significant.

Fourth is supply-chain and operating risk. The company discloses that its U.S. inventory is mainly stored in a single location in Massachusetts and that some components come from a single supplier; for a high-frequency-consumption medical-device company, this is a real vulnerability in terms of geography, natural disasters, and single points of failure.

Fifth is overvaluation risk. The current price is not cheap, and the large Q1 repurchase may have been executed at a relatively high level. If the next three years bring a scenario of "growth stepping down from 20%-30% to 10%-15%"—hardly a disaster—the valuation multiple could compress noticeably, leaving shareholder returns below intuition.

The strongest bear case is actually simple: PODD may be a genuinely excellent company, but the price you pay today already assumes it stays excellent. If reality turns out to be merely "fine" rather than "consistently outstanding," then the return on this investment will be very ordinary. What a bear sees is likely the back-to-back quality events, the still-elevated valuation, the relatively low current cash yield, and a management team that has not yet proven its capital-allocation quality in the mature phase.

For facts that would overturn the investment thesis, I would focus on the following: a sustained decline in Omnipod's new-customer share; gross margin weakening in reverse for several consecutive quarters; recurring quality or regulatory problems; T2D expansion that keeps failing to deliver; capital allocation that keeps doing aggressive repurchases at high valuations; and cash flow returning to a "the more it grows, the more cash it eats" state. If two or three of these hold true at the same time, I would acknowledge that the original judgment needs to be revised.

Investment Checklist

The table below is my long-term-owner checklist, rated "Pass / Fail / Uncertain." Its contents are a composite judgment based on the facts above.

Final Investment Conclusion

【Final Rating】 Watch

【One-Sentence Investment Thesis】 Insulet is a high-quality diabetes-technology company I am willing to track long term and even buy at a better price, but buying at the current price is more about paying for future high growth than acquiring a cash-rich business at a discount.

【Core Bull Case】

• The Omnipod platform is highly focused with a clearly differentiated product form, and its active-customer scale, channel coverage, and physician-prescription base already form a substantial barrier.

• AID's long-term demand has guideline support, and the industry is still in a penetration-rising phase rather than a mature-decline phase.

• Financial quality has improved markedly: revenue grew at a CAGR of about 25% from 2021 to 2025, gross and operating margins kept rising, and free cash flow has turned strong.

• The balance sheet is broadly sound, net debt is manageable, and interest coverage is fairly strong.

• If T2D and international expansion deliver, the current valuation still has upside elasticity.

【Core Bear Case】

• The current valuation is not cheap; the conservative-basis owner's yield is below the 10-year Treasury yield, and the margin of safety is thin.

• The back-to-back quality/manufacturing corrections in 2026 pose real threats to the brand, regulatory relationships, and growth cadence.

• Revenue is highly dependent on intermediaries and large customers, the top three distribution customers are highly concentrated, and Drug Delivery depends on Amgen.

• The top of management has a short tenure, insider ownership is on the low side, and the Q1 2026 repurchase price looks unattractive.

• This is not an asset-protected investment; once growth expectations are revised down, multiple compression will hurt.

【Key Assumptions】

• Omnipod keeps maintaining high new-customer share and high retention in the U.S. and international markets.

• Quality problems are stage-specific and do not evolve into sustained regulatory events.

• T2D market expansion delivers at least partly, rather than staying a long-term "story."

• Gross and operating margins do not retreat noticeably under competitive and reimbursement pressure.

• Management is more restrained and rational in future repurchases and capital allocation.

【Fair Buy Price】 I would seriously consider buying in the $110-120 range. This range corresponds roughly to a 15%-25% discount to the neutral intrinsic value of $130-150 and better fits the margin of safety a "balanced and somewhat conservative" investor needs. The current $144.94 is closer to fair value than to a clear undervaluation.

【Target Holding Period】 If bought, it suits a holding horizon of more than 10 years. This name is least suited to "quarterly trading"; it is best suited to waiting for it to keep delivering on patient scale, T2D expansion, internationalization, and margins.

【Expected Annualized Return】 Based on this report's three-scenario DCF assumptions, starting from the current price, I estimate the long-term annualized return roughly as:

• Conservative scenario: about 7%-8%

• Neutral scenario: about 9%-10%

• Optimistic scenario: about 10%-12%

This is not a bad return, but for a more conservative investor it is not yet good enough to justify ignoring valuation discipline. This return range is an opinion derived from assumptions.

【Maximum Loss Risk】 The worst yet not-unimaginable scenario, in my view, is recurring quality problems, declining share, and pressured margins, together with a valuation that drops from a quality-growth multiple to an ordinary medical-device multiple; in that case, a further decline of 45%-60% from the current price is not impossible. Layer on escalating regulation and litigation, and in extreme cases even larger declines cannot be ruled out. This is an inference, not a forecast.

【Tracking Metrics】

• Omnipod new-customer start share and active-customer count.

• U.S. Omnipod and International Omnipod growth rates.

• Gross margin and operating margin.

• Operating cash flow and free cash flow.

• Receivables and inventory turnover.

• Quality events, MDCs/recalls, and FDA interactions.

• T2D-related clinical and product progress.

• Dexcom/Abbott compatibility and ecosystem-partnership progress.

• Repurchase price and repurchase scale.

• Changes in distribution-customer concentration.

【Signals That Trigger Reassessment】

• A clear decline in new-customer share for two or more consecutive quarters.

• A trend-level decline in gross margin and operating margin.

• Another major quality/recall event whose cost and impact exceed expectations.

• A clear delay in T2D expansion or sustained below-expectation commercialization.

• Large repurchases continuing in a clearly overvalued range.

• Operating cash flow deteriorating again, with "the faster it grows, the shorter it is on cash."

【Final Recommendation】 To put it plainly, PODD deserves respect but does not need to be owned in a hurry. It is a high-quality, understandable company with long-term potential; however, for a balanced, somewhat conservative investor with a holding period of more than 10 years, what truly merits waiting for is not a more compelling story but a thicker margin of safety. If you already own it, I would suggest "hold and watch quality and capital allocation closely"; if you do not yet own it, I would rather place it high on a watch list and act when price or the risk-reward ratio becomes more favorable.

Open Questions and Limitations

In the peer-relative-valuation section, I did not rebuild every competitor on a fully uniform trailing-twelve-month basis item by item, so the EV/Sales figures for DXCM/TNDM are better used as supplementary references than as precise anchors. Another limitation is that some of the industry-share and TAM data come from the company's investor materials and reflect management's perspective, and should be continually verified against subsequent public market data.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.